PROSPECTUS
60,000,000 Shares

Medline Inc.
Class A Common Stock
The selling stockholders named in this prospectus are offering 60,000,000 shares of our Class A common stock. Our shares of Class A common stock are listed on the Nasdaq Global Select Market (“Nasdaq”) under the trading symbol “MDLN.”
We and Medline Holdings (as defined herein) have agreed to repurchase an aggregate of $200 million of shares of our Class A common stock and Common Units (as defined herein) directly from the selling stockholders in a private, non-underwritten transaction at a price per equity interest of $35.05625, which is the price paid by the underwriters in this offering (the “Repurchase”). Accordingly, we expect to repurchase an aggregate of 3,788,113 shares of Class A common stock and 1,916,994 Common Units in the Repurchase. To the extent that Common Units are repurchased from a selling stockholder, upon the closing of the Repurchase, such selling stockholder will also transfer an equivalent number of shares of Class B common stock to us for no additional consideration, and such shares of Class B common stock will be cancelled and retired. The Repurchase is expected to close concurrently with the offering and is conditioned upon the closing of this offering. The closing of this offering is not conditioned upon the closing of the Repurchase. See “Summary—Share and Unit Repurchase.”
On November 17, 2026, the closing sales price of our shares of Class A common stock as reported on Nasdaq was $37.68 per share. We will not receive any proceeds from the sale of shares of our Class A common stock by the selling stockholders. Prior to the consummation of this offering, certain of the selling stockholders will exchange Common Units for shares of our Class A common stock to be sold by them in the offering. See “Principal and Selling Stockholders.”
Investing in shares of our Class A common stock involves risks. See “Risk Factors” beginning on page 20 to read about factors you should consider before buying shares of the Class A common stock.
Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.
|
Per Share |
|
|
Total |
|
||
Public offering price |
$ |
35.50 |
|
|
$ |
2,130,000,000 |
|
Underwriting discounts and commissions(1) |
$ |
0.44375 |
|
|
$ |
26,625,000 |
|
Proceeds, before expenses, to the selling stockholders |
$ |
35.05625 |
|
|
$ |
2,103,375,000 |
|
The underwriters have the option to purchase up to an additional 9,000,000 shares of our Class A common stock from the selling stockholders at the public offering price less the underwriting discounts and commissions within 30 days from the date of this prospectus.
The underwriters expect to deliver the shares of our Class A common stock against payment in New York, New York on or about November 23, 2026.
Global Coordinators and Joint Bookrunning Managers |
|||
Goldman Sachs & Co. LLC |
Morgan Stanley |
||
BofA Securities |
J.P. Morgan |
||
Joint Bookrunning Managers |
|||
Barclays |
Citigroup |
Deutsche Bank Securities |
|
Jefferies |
|
UBS Investment Bank |
|
|
Evercore ISI |
|
|
BMO Capital Markets |
BNP PARIBAS |
MUFG |
|
RBC Capital Markets |
Santander |
Societe Generale |
|
TD Cowen |
Wells Fargo Securities |
Wolfe | Nomura Alliance |
|
Leerink Partners |
Macquarie Capital |
Mizuho |
|
Piper Sandler |
Truist Securities |
William Blair |
|
Co-Managers |
|||
Blackstone Capital Markets |
|
Carlyle |
|
Baird |
Rothschild & Co |
Stifel |
|
BTIG |
ING |
IMI - Intesa Sanpaolo |
|
NCMG |
|
Perella Weinberg |
|
Academy Securities |
Blaylock Van, LLC |
C.L. King & Associates |
|
Drexel Hamilton |
Loop Capital Markets |
Mischler AmeriVet |
|
R. Seelaus & Co., LLC |
Ramirez & Co., Inc. |
Siebert Williams Shank |
|
|
Tigress Financial Partners |
|
|
The date of this prospectus is November 17, 2026.










